KA/EN
Register
Medicines reference
Search
Search
Product

Venter

Favourites

Sucralfate · KRKA, d.d., Novo mesto

1 form: scored tablet. No registration in force in Georgia.

Forms and doses0 of 1 in force in Georgia

Form Dose Frequency Georgia
1 g tablet, Scored tablet No label dose in the reference yet - Georgia No longer listed
Was registered; not in the current register
Human (Ministry of Health, RAMA)
In the register: ვენტერი 1000 მგ
№ რ-023029
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Venter 1 g tablet, Scored tablet

human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified
5.0/10
Weak evidence support
vetman assessment

Venter

1 g tablet, human medicine
Assessed clinical scopeDog · Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified · By mouth
Care settingVeterinarian-directed outpatient or inpatient adjunct after defining the lesion, primary cause, concurrent treatment and interaction schedule
vetman score 5.0/10 Weak evidence support
Evidence confidence: Medium Georgia: No longer listed · № რ-023029 · Verified on 22 Oct 2026 Off-label use

A selectively useful but weakly evidenced human-product adjunct. Exact-product transparency is acceptable, while limited outcome evidence, PPI superiority, interactions and unreliable intact-tablet performance constrain value.

Regulatory and scientific credibility5.5/10

Exact current Slovenian human product information and status are transparent, but Georgia is expired, veterinary authorisation is absent and exact-product veterinary outcome evidence is limited.

Clinical efficacy4.0/10

A plausible mucosal barrier effect and professional dosing guidance exist, but animal outcome evidence is limited, PPIs are superior and routine addition to adequate acid suppression is unsupported.

Safety and tolerability6.0/10

Low systemic absorption is favourable, but constipation, bezoar risk, aluminium accumulation in renal dysfunction and clinically important absorption interactions remain.

Clinical practicality4.0/10

Frequent fasting/separated dosing and unreliable intact-tablet disintegration are burdensome. Water dispersion is possible, but the score line does not validate an accurate 500 mg fraction.

Full-course cost-effectiveness-

Current exact-product Georgian price and availability were not verified; cost is excluded.

Important safety and use flags

  • Use only for a selected confirmed or strongly suspected upper-GI ulcerative/erosive lesion when sucralfate has a defined role. PPIs are generally superior and routine add-on benefit is unsupported.
  • Do not administer the tablet intact when reliable local activity is required. Disperse it in water according to the exact product information or select a suitable suspension.
  • The score line does not establish equal-dose halves or quarters. Do not invent 500 mg or 250 mg accuracy from visual subdivision of this 1 g tablet.
  • Give apart from food and interacting oral medicines by the interval applicable to the other medicine and clinical protocol; adsorption/chelation can cause treatment failure.
  • Interaction magnitude is drug-specific. Direct evidence supports marked doxycycline and ciprofloxacin effects, while enrofloxacin was not materially changed; marbofloxacin carries its own label warning.
  • Avoid or strictly limit in renal dysfunction because aluminium may accumulate. In a small feline CKD study, three of five treated cats clinically decompensated.
  • Monitor vomiting, anorexia, constipation, hydration, azotaemia and bezoar or impaired-motility risk; reassess promptly if the patient worsens.
  • Pregnancy and lactation safety data are insufficient in dogs and cats. Minimal absorption is a pharmacological inference, not proof of reproductive safety.
  • The exact Georgian Venter 1000 mg registration expired in 2022. Another sucralfate brand, concentration or formulation does not transfer market status to this tablet.
  • This is extra-label cascade use of a human medicine in dogs and cats. Document the reason, exact preparation method, dose source, interaction schedule and response endpoint.
Assessment sources
  1. Venter Slovenia record2026
  2. Venter Slovenia PIL2013
  3. Venter Georgia audit2026
  4. ACVIM GI-protectant consensus2018
  5. Merck GI-ulcer pharmacology2025
  6. Merck small-animal GI ulcers2025
  7. Canine tablet-dispersion study2015
  8. Feline CKD sucralfate study2016
  9. Canine fluoroquinolone interaction2016
  10. Carafate FDA label2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified
4.2/10
Weak evidence support
vetman assessment

Venter

1 g tablet, human medicine
Assessed clinical scopeCat · Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified · By mouth
Care settingVeterinarian-directed outpatient or inpatient adjunct after defining the lesion, primary cause, concurrent treatment and interaction schedule
vetman score 4.2/10 Weak evidence support
Evidence confidence: Medium Georgia: No longer listed · № რ-023029 · Verified on 22 Oct 2026 Off-label use

A weakly evidenced human-product adjunct with a poor feline dose-form fit and a direct CKD safety signal. Use only when its specific mucosal role clearly justifies those limitations.

Regulatory and scientific credibility5.5/10

Exact current Slovenian human product information and status are transparent, but Georgia is expired, veterinary authorisation is absent and exact-product veterinary outcome evidence is limited.

Clinical efficacy3.5/10

The same mechanistic rationale applies, but feline clinical-outcome evidence is even thinner; PPIs are superior and routine addition to adequate acid suppression is unsupported.

Safety and tolerability4.5/10

Low systemic absorption is favourable, but direct feline data found vomiting and decompensation in three of five CKD cats at a referenced upper regimen, alongside constipation and aluminium concerns.

Clinical practicality2.5/10

Frequent separated dosing, unreliable intact-tablet disintegration and an unvalidated fractional 1 g unit are particularly poorly matched to cats; water dispersion does not make visual quarters dose-accurate.

Full-course cost-effectiveness-

Current exact-product Georgian price and availability were not verified; cost is excluded.

Important safety and use flags

  • Use only for a selected confirmed or strongly suspected upper-GI ulcerative/erosive lesion when sucralfate has a defined role. PPIs are generally superior and routine add-on benefit is unsupported.
  • Do not administer the tablet intact when reliable local activity is required. Disperse it in water according to the exact product information or select a suitable suspension.
  • The score line does not establish equal-dose halves or quarters. Do not invent 500 mg or 250 mg accuracy from visual subdivision of this 1 g tablet.
  • Give apart from food and interacting oral medicines by the interval applicable to the other medicine and clinical protocol; adsorption/chelation can cause treatment failure.
  • Interaction magnitude is drug-specific. Direct evidence supports marked doxycycline and ciprofloxacin effects, while enrofloxacin was not materially changed; marbofloxacin carries its own label warning.
  • Avoid or strictly limit in renal dysfunction because aluminium may accumulate. In a small feline CKD study, three of five treated cats clinically decompensated.
  • Monitor vomiting, anorexia, constipation, hydration, azotaemia and bezoar or impaired-motility risk; reassess promptly if the patient worsens.
  • Pregnancy and lactation safety data are insufficient in dogs and cats. Minimal absorption is a pharmacological inference, not proof of reproductive safety.
  • The exact Georgian Venter 1000 mg registration expired in 2022. Another sucralfate brand, concentration or formulation does not transfer market status to this tablet.
  • This is extra-label cascade use of a human medicine in dogs and cats. Document the reason, exact preparation method, dose source, interaction schedule and response endpoint.
Assessment sources
  1. Venter Slovenia record2026
  2. Venter Slovenia PIL2013
  3. Venter Georgia audit2026
  4. ACVIM GI-protectant consensus2018
  5. Merck GI-ulcer pharmacology2025
  6. Merck small-animal GI ulcers2025
  7. Canine tablet-dispersion study2015
  8. Feline CKD sucralfate study2016
  9. Canine fluoroquinolone interaction2016
  10. Carafate FDA label2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sucralfate1000 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
KRKA, d.d., Novo mesto · Slovenia
Registration
Georgia No longer listed
Was registered; not in the current register
Human (Ministry of Health, RAMA)
In the register: ვენტერი 1000 მგ
№ რ-023029
Verified on: 22 Oct 2026
 EU Yes, human
№ 5363-I-2084/09
Verified on: 22 Oct 2026
 UK Not confirmed
Unresolved exact-product endpoint
Verified on: 22 Oct 2026
 US Not confirmed
Unresolved exact-product endpoint
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Veterinarian-directed extra-label use only for selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified. Do not give the tablet intact when reliable local activity is required: disperse it in water according to the exact product information or use a suitable suspension. The score line does not validate equal halves or quarters, so do not calculate an unverified fractional tablet dose.

Sucralfate: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical (Cat)
    In a small study of cats with chronic kidney disease and normal phosphate, three of five cats given sucralfate deteriorated (vomiting, loss of appetite, constipation, worsening azotaemia). The study was stopped because of these effects and the lack of benefit, which contradicts the usual claim that sucralfate has almost no adverse effects.
    Sources: MSD Vet Manual
  • Warning
    In renal failure, aluminium absorption from sucralfate may increase. Prolonged treatment can therefore increase the risk of aluminium toxicity and requires caution.
    Sources: ACVIM · MSD Vet Manual
  • Warning
    Contraindicated in known hypersensitivity to sucralfate or any excipient. Reported hypersensitivity reactions include dyspnoea, rash, urticaria, anaphylaxis, and bronchospasm.
    Sources: FDA
  • Warning
    No pregnancy data are available in dogs or cats. Sucralfate is minimally absorbed, making systemic exposure less likely, but this is a pharmacological inference rather than evidence of safety.
    Sources: MSD Vet Manual
  • Warning
    No lactation data are available in dogs or cats. Minimal absorption makes systemic exposure less likely, but this remains a pharmacological inference rather than evidence of safety.
    Sources: Product label
  • Caution
    Sucralfate is less effective than a proton pump inhibitor for gastrointestinal ulceration and erosion, and there is no evidence that adding it to a proton pump inhibitor or an H2 blocker brings extra benefit. If a proton pump inhibitor is already given, adding sucralfate is not justified.
    Sources: ACVIM · MSD Vet Manual

Known Drug Interactions

  • Major warning Marbofloxacin + Sucralfate
    Sucralfate, antacids, and mineral supplements containing iron, aluminium, calcium, magnesium, zinc, or other divalent or trivalent cations can reduce quinolone absorption and bioavailability. The magnitude is drug-specific; marbofloxacin is covered by a direct product warning.
    Recommendation: Avoid concurrent oral administration. If both medicines are necessary, separate sucralfate or the cation-containing product from the quinolone by at least 2 hours and monitor clinical response.
    Sources: VMD SPC · VMD · FDA · ACVIM · JVIM
  • Major warning Doxycycline + Sucralfate
    In dogs, concurrent administration of sucralfate suspension reduced doxycycline AUC from 36.0 to 7.2 h·mcg/mL (relative bioavailability 20%). No interaction was detected with sucralfate tablets because tablet fragments were visible in faeces, indicating that the tablets did not disintegrate and were not effective.
    Recommendation: Separate administration by 2 hours: give doxycycline first and sucralfate 2 hours later. With this schedule, bioavailability is 74% and is not statistically different from doxycycline alone.
    Sources: JVPT
  • Minor warning Sucralfate + Levothyroxine
    Antacids containing aluminium, magnesium, or calcium, as well as ferrous sulfate and sucralfate, can reduce levothyroxine absorption.
    Recommendation: Separate levothyroxine from antacids, iron, or sucralfate by at least 2 hours.
  • Minor warning Enrofloxacin + Sucralfate
    The concomitant administration of substances containing magnesium or aluminium may reduce the absorption of enrofloxacin. These drugs should be administered two hours apart.
    Recommendation: Separation is not critical in dogs, but a 2-hour interval is safe and label-consistent. No comparable measurement exists in cats; use a 2-hour interval in cats.
    Sources: VMD SPC · VMD · JVIM
  • Minor warning Oxytetracycline + Sucralfate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (41 more) Hide additional products

Same therapeutic group 41

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗